Hypercholesterolaemia
Red Flags — establish whether this is already secondary prevention
| Red flag | Why it matters | Action |
|---|---|---|
| Chest pain on exertion relieved by rest (angina) | Established coronary artery disease = secondary prevention. Atorvastatin 80mg (not 20mg) regardless of cholesterol. Also: aspirin, ACEi, beta-blocker, GTN. Exercise ECG or CT coronary angiography. This changes the entire management priority. | ECG; urgent cardiology referral; atorvastatin 80mg; aspirin; ACEi |
| TIA symptoms: transient weakness, speech disturbance, unilateral visual loss | TIA = established cerebrovascular disease = secondary prevention. If acute (<24h): 999 if symptoms ongoing; ALL suspected TIA → specialist review within 24h (NG128). Atorvastatin 80mg; aspirin + clopidogrel (acute TIA); hypertension management. | Suspected TIA: same-day referral for specialist review within 24h (NG128); aspirin 300mg; atorvastatin 80mg |
| Intermittent claudication (calf pain on walking, relieved by rest) | Peripheral arterial disease (PAD) = established atherosclerosis = secondary prevention. Ankle-brachial index (ABI) <0.9 confirms PAD. Atorvastatin 80mg; aspirin; tight BP and glycaemic control; smoking cessation is critical in PAD (most powerful intervention for PAD progression). | ABI measurement; vascular surgery referral; atorvastatin 80mg; aspirin; smoking cessation critical |
| Acute chest pain, diaphoresis, arm or jaw pain | Acute MI: 999 immediately. This is not a lipid clinic consultation at this point — it is a cardiac emergency. If discovered incidentally during a medication review: assess clinically; activate 999; do not delay for any other agenda. | 999; aspirin 300mg; GTN if available; lie patient down; do not leave alone |
| Sudden-onset severe headache or unilateral weakness (stroke symptoms) | Ischaemic stroke: FAST (Face, Arms, Speech, Time). If acute: 999; do not give aspirin (haemorrhagic stroke excluded by CT first). High-dose statin after confirmed ischaemic stroke. | 999 if acute stroke; CT head before aspirin; atorvastatin 80mg after confirmed ischaemic stroke |
| Xanthomata, xanthelasma, or corneal arcus in patient under 45 | Cutaneous xanthomata (tendon or tuberous): highly specific for FH or other severe dyslipidaemia. Xanthelasma (periorbital lipid deposits): associated with elevated LDL; less specific for FH. Corneal arcus under 45: associated with FH. Any of these in a primary care patient warrants urgent total cholesterol + lipid profile + specialist referral. | Urgent fasting lipid profile; Simon Broome criteria check; specialist lipid clinic referral; cascade family screening |
Safeguarding and Occupational Considerations
🚛 Occupational CVD Risk — HGV Driving
- David is an HGV lorry driver: any cardiovascular event (MI, stroke, significant arrhythmia) would mean mandatory DVLA notification and potential loss of Group 2 licence
- DVLA Group 2 (HGV/PSV): MI — 6 weeks off; can return if LVEF >40%, no angina, exercise ECG satisfactory; stroke/TIA — 12 months off Group 2; sudden incapacity (AF, arrhythmia) — complex; specialist review
- The real occupational threat is NOT statin myopathy (rare) but an untreated MI or stroke (18% 10-year risk untreated)
- Reframing: "the medication that protects your livelihood is the statin — the thing that threatens it is having a heart attack"
💊 Medication Adherence in Long-Distance Drivers
- Long-haul HGV driving disrupts medication routines — irregular mealtimes; limited healthy food options at motorway services; fatigue driving poor dietary choices
- Practical prescribing: once-daily statin (atorvastatin) is ideal — can be taken at same time daily regardless of meal; can be taken at night; depot injections (inclisiran) particularly advantageous for poor adherence (twice-yearly)
- Metformin: significant GI side effects at motorway cafes; extended-release metformin reduces GI effects; discuss with David
- BP medication: amlodipine once-daily — appropriate; check BP control at this visit
🧠 Mental Health and CVD Risk
- Severe mental illness (schizophrenia, bipolar disorder): included in QRISK3 as a risk multiplier; antipsychotics cause metabolic syndrome (weight gain; dyslipidaemia; glucose intolerance)
- Depression: independently associated with increased CVD risk; poor medication adherence; reduced physical activity; higher smoking rates; poor diet
- David: driving job + long hours + physical isolation + financial pressure of self-employment = significant stress burden; PHQ-9 opportunistically
- Alcohol 16 units/week: mood management drinking? AUDIT full questionnaire if AUDIT-C positive
🌍 Ethnicity and CVD Risk
- South Asian ethnicity: higher CVD risk than white European at equivalent QRISK3 inputs; QRISK3 applies an ethnicity multiplier; type 2 diabetes more common; onset earlier; worse cardiovascular outcomes; statin threshold should be lower in South Asian high-risk groups
- Black African/Caribbean: lower CVD event risk but higher stroke and heart failure risk; QRISK3 applies ethnicity-specific risk adjustments
- FH: all ethnicities; but founder mutations in some populations (e.g. Lebanese origin — higher FH rate)
- Always document ethnicity for QRISK3 accuracy; do not assume from name
📊 Risk Communication
Abstract percentage risks feel remote. Concrete framing changes the conversation: "18% means that out of 100 men exactly like you — same age, same smoking, same diabetes, same blood pressure — 18 of them will have a heart attack or stroke in the next 10 years without treatment. The statin reduces that to about 13 of those 100. Over 10 years, smoking cessation would prevent even more." This personalised framing with a defined population reference point is more persuasive than "your risk is elevated."
"I want to put some numbers to this. Without treatment, in the next 10 years, your risk of a heart attack or stroke is about 18 in 100. The statin brings that to about 13 in 100. Stopping smoking would probably bring it down further. Those numbers are about you specifically — not averages."🚛 Occupational Threat Reframing
David’s primary resistance is occupational (HGV licence). The reframe: a myocardial infarction or stroke would end his HGV career far more certainly than statin myopathy. DVLA Group 2: after MI, he would be off Group 2 licence for at least 6 weeks (return only if LVEF >40%, no angina, satisfactory exercise ECG). After stroke: 12 months off Group 2. After sudden incapacity: complex; specialist review. Severe statin myopathy (the kind that stops someone working): 1-3 per 100,000 patient-years. His 10-year cardiovascular event risk: 18 in 100. The statin protects his licence far more than it threatens it.
"I want to address the lorry directly. If you have a heart attack — which at your risk level is a real possibility — you will be off your Group 2 licence for at least 6 weeks, and possibly much longer depending on how well your heart recovers. The muscle problem severe enough to stop driving happens in about 1-2 people per 100,000 on statins. The statin is protecting your ability to drive, not threatening it."🚬 Smoking — the highest-yield conversation
For David, the single most impactful CVD risk reduction available is smoking cessation. It is more effective than the statin, free, and addresses multiple risk factors simultaneously (blood pressure, HDL, LDL oxidation, endothelial function, clotting). The consultation should include a brief smoking cessation intervention regardless of whether the statin conversation reaches agreement. Ask about readiness to stop; offer NHS Stop Smoking service referral; discuss varenicline or combination NRT. The patient who stops smoking AND starts a statin is far better protected than the patient who starts a statin but continues smoking.
"If you do one thing today that will have the biggest effect on your heart risk, stopping smoking is it — more than the statin. I am not using that to get out of the statin conversation, but I do want to know: is stopping smoking something you are willing to consider? Because the NHS has a brilliant free service that doubles your success rate."🍺 Alcohol as CVD Risk
David’s 16 units/week is above the recommended 14, contributes to his elevated triglycerides, and adds to LFT elevation risk before starting a statin. The alcohol conversation in this context is about cardiovascular risk, not addiction management. Brief intervention: "Cutting to 14 units would reduce your triglycerides and improve your liver test results, which we need to check before the statin." This frames alcohol reduction as a practical, achievable step with a concrete benefit — more motivating than a generic "you should drink less."
"Your triglycerides are mildly elevated — that’s partly the diabetes and partly the alcohol. If you could reduce by even 2 or 3 units a week, that would improve the triglycerides and the liver tests I need before I prescribe the statin."- Presenting risk score without asking about the statin refusal first — misses ICE; paternalistic; fails Relating to Others domain
- Dismissing the myopathy concern — "it’s very rare, don’t worry" without specific framing; patient leaves feeling unheard
- Not mentioning smoking cessation as the most impactful intervention — significant missed clinical opportunity
- Not calculating or communicating the QRISK3 score in personalised, plain-language terms
Atorvastatin 80mg — Start Now
All established CVD — no QRISK3 needed- Prior MI, ACS, stable anginaAtorvastatin 80mg OD; aspirin; ACEi; beta-blocker; cardiac rehab; LDL target <1.4 mmol/L
- Prior stroke (ischaemic) or TIAAtorvastatin 80mg; antiplatelet; antihypertensive; LDL target <1.4 mmol/L
- Peripheral arterial diseaseAtorvastatin 80mg; aspirin; smoking cessation critical; vascular surgery review
- Acute CVD event presenting in GP999; aspirin 300mg; GTN; atorvastatin 80mg on discharge
Specialist Lipid Clinic
High-intensity statin + specialist- Total cholesterol >7.5 mmol/L + family history premature CVDSimon Broome criteria — FH; urgent specialist lipid clinic; cascade screening
- Tendon xanthomata, corneal arcus (<45), xanthelasmaUrgent lipid profile; FH assessment; specialist referral
QRISK3 → Shared Decision
David — QRISK3 18.3%- QRISK3 ≥10%: offer statin after discussionAtorvastatin 20mg first-line; lifestyle optimisation concurrent; LFTs first; 3-month target check
- QRISK3 <10%: lifestyle optimisation and reassessRepeat QRISK3 in 5 years; address modifiable factors (smoking, diet, exercise)
- Using atorvastatin 80mg for primary prevention (correct dose is 20mg for primary prevention per NICE NG238)
- Not checking BP when seeing a patient for CVD risk assessment — BP is a core component of total CVD risk and must be measured
- Starting statin without LFT check — NICE NG238 requires LFTs before statin initiation; mandatory baseline
"I want to explain what your cardiovascular risk score actually means. I put all of your information into a calculator — your age, your blood pressure, your cholesterol, your diabetes, the smoking, and the fact that you’re carrying a bit of extra weight. The result was 18%. What that means is: if we imagine 100 men exactly like you — same age, same health profile — 18 of those 100 men will have a heart attack or stroke in the next 10 years if nothing changes. The other 82 won’t. So there is no emergency today, and it’s not a certainty. But 18 in 100 is a significant enough number that it makes sense to do something about it. The statin could reduce that from 18 to about 13 in 100. Stopping smoking could reduce it further. Both together would be the most powerful combination available."
"I exercise and watch my diet — can’t that bring the risk down enough?"
"Lifestyle changes absolutely help — and I want to talk about them. But I want to be honest with you. At 18%, even with excellent diet and exercise, your risk is unlikely to fall below 10% — because your age, your diabetes, and your blood pressure are driving a significant part of it that lifestyle alone doesn’t fully address. The best result would be: lifestyle changes AND a statin AND stopping smoking — that combination would bring your risk down the most. I don’t want you to feel you have to choose between lifestyle and medication."
"Is there no way to do this without tablets?"
"The honest answer is: at your risk level, lifestyle alone is unlikely to be enough. Stopping smoking would make the biggest single difference — that is genuinely more impactful than the statin. But the statin, at a low dose, has a very well-established safety record over decades. And I want to specifically address the muscle concern — because I think that is really what is driving your hesitation."
Myalgia (muscle ache)
Common (5-10%); does NOT indicate myopathy; check CK before stopping; often resolves with dose reduction or switch to rosuvastatin/pravastatin (hydrophilic; lower myopathy risk).
Myopathy (CK >4× ULN)
Rare (1-3 per 100,000 patient-years); stop statin; CK monitoring; usually resolves after cessation. Rhabdomyolysis (>10× ULN): very rare; medical emergency; IV fluids.
Atorvastatin 80mg
NICE NG238: all secondary prevention patients. No QRISK3 needed. No cholesterol threshold. Start regardless of baseline lipid level.
Target: LDL <1.4 mmol/L
If not at target: add ezetimibe; then PCSK9 inhibitor (specialist). Non-HDL target <2.2 mmol/L.
- Presenting QRISK3 as a percentage without concrete framing — "18% risk" is less meaningful than "18 in 100 men like you"; the SCA candidate who uses personalised framing scores higher in Relating to Others
- Referring David to a lipid specialist before trying first-line treatment — not indicated; primary prevention with standard QRISK3 is managed in primary care
Validate the concern — his friend’s story is real
David has a first-hand account of a person whose statin caused severe muscle problems that stopped them working. This is a real experience and must be acknowledged as real before any statistical information is useful. "I understand why that story would make you cautious — and your friend’s experience was clearly very difficult."
"What happened to your friend sounds genuinely awful, and I completely understand why that story would make you think carefully before starting the same medication. I want to give you the accurate information so you can make the best decision for yourself."Provide specific, accurate information about myopathy rates
Generic "it’s rare" does not address the fear. Specific numbers do: severe myopathy occurs in 1-3 people per 100,000 patient-years. Rhabdomyolysis (the most severe form) is even rarer. Mild muscle ache occurs in 5-10% and is managed by dose reduction or switching statin. The CK monitoring protocol means the GP catches myopathy early, before it causes the kind of harm David’s friend experienced.
"The severe muscle problem your friend had — the kind that would stop someone driving — happens in about 1 to 2 people per 100,000 on statins. That is very rare. Mild muscle ache, which is more common — about 5 to 10 people in 100 — is manageable: we change the dose or change the tablet. And we have a blood test we check early on to catch any muscle problem before it gets serious."Reframe the occupational risk — the heart attack is the real threat to his licence
David’s primary motivation is protecting his HGV licence and livelihood. The reframe requires making the cardiovascular risk as concrete and occupationally relevant as the myopathy fear: DVLA Group 2 after MI = 6 weeks off licence minimum; after stroke = 12 months. His 18% risk over 10 years is far more likely to threaten his career than statin myopathy at 1 per 100,000.
"I want to put both risks to you in lorry terms. The muscle problem severe enough to stop you driving: 1 in 100,000. A heart attack at your risk level in the next 10 years: around 18 in 100. If you have a heart attack, DVLA takes your Group 2 licence for at least 6 weeks — and sometimes much longer. The statin is not the risk to your licence. The untreated heart attack is."Smoking is the single most impactful modifiable CVD risk factor in David’s profile. Cessation reduces 10-year CVD risk by approximately 30-50% within the first year of stopping. Effect on lipids: smoking reduces HDL (protective cholesterol); stopping smoking raises HDL by 5-10% within weeks. Smoking also increases LDL oxidation (oxidised LDL is the atherogenic form) and promotes platelet aggregation and endothelial dysfunction. Stopping smoking addresses multiple mechanisms simultaneously.
5As: Ask; Advise; Assess (readiness); Assist (varenicline or combination NRT); Arrange (NHS Stop Smoking Service referral). Varenicline (cytisine): 90% more effective than placebo; most effective pharmacotherapy; check mental health history (can worsen depression; MHRA warning — monitor mood). Combination NRT (patch + fast-acting): second-line. NHS Stop Smoking Service: free; qualified advisors; doubles success rate compared to unassisted cessation.
Mediterranean diet: strongest dietary evidence for CVD risk reduction (PREDIMED trial); reduces MACE by 30% in high-risk patients; emphasises olive oil, vegetables, legumes, fish, nuts, whole grains; restricts processed foods, red meat, saturated fat. Saturated fat: raises LDL-C; target <10% of total energy; replace with unsaturated fats (olive oil, rapeseed oil). Plant sterols/stanols (2g/day: yoghurt drinks, spreads): reduce LDL-C by 10-15% independently of diet; mechanism: compete with cholesterol absorption in GI tract. Oily fish (2 portions/week): reduces triglycerides; reduces cardiovascular mortality.
Lorry-driver diet: motorway services food is typically high saturated fat, low fibre. Practical advice: packed lunch (whole grain sandwich, nuts, fruit); avoid fried food at motorway stops; swap crisps for nuts; two oily fish meals per week. Plant sterol yoghurt drink once daily: simple, portable, effective 10% LDL reduction.
Regular aerobic exercise: raises HDL-C (5-10%); modestly lowers LDL-C (5%); reduces triglycerides (10-20%); reduces blood pressure; improves insulin sensitivity; reduces weight. Independent CVD mortality reduction of approximately 30% with 150 min/week of moderate activity. For David: HGV driving is sedentary. Exercise outside work hours is essential. Brisk walking, cycling, swimming: all count. HIIT (high-intensity interval training): highly effective for metabolic syndrome; 20 minutes equivalent to 45 minutes moderate activity for CVD benefits.
Short periods at lorry stops (walk around the lorry park; 10 minutes brisk walking when stationary); daily target total 30 minutes in shorter bursts; exercise app or step counter; evening activity after work. Even 30 minutes of brisk walking 5 days/week achieves most of the CVD benefit.
Excessive alcohol (David: 16 units/week) significantly raises triglycerides and is a major contributor to his TG 2.2 mmol/L. Alcohol also elevates blood pressure and contributes to weight gain. Effect of alcohol on HDL: moderate alcohol (up to 14 units/week) mildly raises HDL — but this does not offset the TG elevation, BP effect, and liver toxicity. The LFT check before statin may show GGT/ALT elevation — address alcohol reduction as part of enabling safe statin initiation. AUDIT-C score: calculate at this appointment. AUDIT positive (≥5 in men): brief intervention (FRAMES).
Reduce to 14 units/week (UK maximum); spread across at least 3 days; avoid binge drinking (lorry-driver culture: weekend binge risk). Two alcohol-free days minimum per week. Address the functional role of alcohol (stress relief after long hauls) — suggest alternatives: exercise; sleep; stress management.
5-10% weight loss in David (5-8kg): reduces LDL-C by 5-10%; reduces TG by 10-20%; raises HDL by 5%; reduces blood pressure; improves HbA1c. Weight loss is synergistic with statin therapy and reduces absolute CVD risk. GLP-1 receptor agonists (semaglutide — Ozempic/Wegovy): 10-15% weight loss; independent CVD event reduction in T2DM (LEADER trial: liraglutide; SUSTAIN-6: semaglutide); NICE NG28 pathway for T2DM + BMI ≥30 + high CVD risk. Tirzepatide (Mounjaro): GIP + GLP-1 agonist; 15-20% weight loss; MACE reduction (SURMOUNT-MMO trial).
Tier 3 weight management service: multi-disciplinary; behaviour change + dietitian + pharmacotherapy. Bariatric surgery: if BMI >40 or BMI >35 + comorbidities; significant LDL, TG, and HbA1c improvements post-surgery.
David has T2DM + QRISK3 >10%: NICE NG28 recommends SGLT2 inhibitor (empagliflozin or dapagliflozin) as add-on to metformin when HbA1c is above target AND CVD risk is high. Mechanism of CVD protection: independent of glycaemic effect; reduces heart failure hospitalisation by 35%; reduces MACE by 14% (EMPA-REG OUTCOME trial); reduces progression of CKD; modest weight loss (~2kg); modest BP reduction. Check eGFR before starting: dapagliflozin avoid if eGFR <25; empagliflozin reduce to 10mg if eGFR 30-45. Check LFTs — no significant interaction with statin.
Once daily tablet; continue metformin alongside; monitor for UTI and genital mycotic infections (most common side effect); counsel on sick day rules (stop SGLT2 inhibitor if unwell, not eating, or peri-operatively — DKA risk); foot hygiene (increased genital infection risk particularly in diabetics). Ensure adequate hydration (lorry driving — carry water).
- Atorvastatin 20mg OD (primary prevention; QRISK3 ≥10%; taken at any time of day; atorvastatin active form — not prodrug; night dosing NOT required unlike simvastatin)
- LFTs and TFTs before starting; repeat LFTs only if symptomatic (not routinely at 3 months unless LFTs were elevated at baseline)
- 3-month review: fasting lipid profile; ≥40% reduction in non-HDL from baseline; if not at target: increase to 40mg or add ezetimibe 10mg
- Consider atorvastatin 40mg from outset if: T2DM with complications; multiple risk factors; HbA1c >70; strong family history premature CVD
- Atorvastatin 80mg OD — regardless of baseline LDL-C; no cholesterol threshold applies
- Target: LDL-C <1.4 mmol/L or non-HDL <2.2 mmol/L at 3 months
- If not at target: add ezetimibe 10mg (LDL reduces further 15-20%); if still not at target: refer specialist lipid clinic for PCSK9 inhibitor (NICE TA394)
- If atorvastatin 80mg not tolerated: try rosuvastatin 40mg; if still intolerant: lower dose statin + ezetimibe; if truly statin-intolerant: ezetimibe + PCSK9 inhibitor (specialist)
- Myalgia (CK normal): reduce dose; try hydrophilic statin (rosuvastatin 5-10mg; pravastatin 40mg — lower myopathy risk); alternate-day dosing; CoQ10 supplement (limited evidence but harmless)
- CK 4-10× ULN: stop statin; confirm resolution; rechallenge with different statin after 4 weeks; monitor CK
- CK >10× ULN (rhabdomyolysis): STOP IMMEDIATELY; IV fluids; monitor renal function; urgent medical review
- If truly statin-intolerant: ezetimibe 10mg monotherapy (20-25% LDL reduction); bempedoic acid 180mg OD (NICE approved; oral; 15-25% LDL reduction; not statin; different mechanism); PCSK9 inhibitor (specialist)
- Atorvastatin 40-80mg or rosuvastatin 20-40mg from diagnosis; do not wait for specialist
- Target: ≥50% reduction in LDL-C from untreated baseline (or LDL-C <2.5 mmol/L in adults)
- Add ezetimibe if target not met; PCSK9 inhibitor if LDL-C >5.0 mmol/L on max statin + ezetimibe (NICE TA394)
- Cascade screening: all first-degree relatives; DNA test for ATP7B mutations if available
- Inclisiran (Leqvio): siRNA; 50% LDL reduction; two injections in year one (Day 1 and Day 90), then once every 6 months; NICE approved for secondary prevention and FH; hospital/specialist prescribing; extremely useful for adherence-poor patients
- Bempedoic acid (Nilemdo): ATP-citrate lyase inhibitor; oral; 15-25% LDL reduction; active in liver not muscle (less myopathy risk); NICE approved for statin-intolerant patients; may rarely cause gout; avoid in CKD <30
- PCSK9 inhibitors (evolocumab/alirocumab): 50-60% LDL reduction; injectable fortnightly or monthly; specialist prescribing; NICE TA394/TA393
Select patient scenario — personalised statin recommendation
"This tablet reduces the cholesterol that builds up in artery walls. You take one tablet every day — at any time, with or without food. The muscle problem you mentioned can happen, but severe muscle problems are very rare — about 1 in 100,000. Mild muscle ache can happen in about 5-10% of people, and if that occurs, we check a blood test and either reduce the dose or try a different tablet. The most important message: do not stop taking it without talking to me first — especially if you think you might be having side effects, because the answer is usually to adjust, not to stop."
Atorvastatin: NICE NG238 first-line. 20mg primary prevention; 80mg secondary. Active drug — take at any time (no night dosing required). Safe with amlodipine at standard doses. LFTs before starting (not routinely repeated). CK only if symptomatic. ≥40% non-HDL reduction at 3 months. Myalgia: check CK; do not stop without investigation. Pregnancy: STOP immediately. Simvastatin + amlodipine: avoid (max 20mg insufficient; use atorvastatin instead).
"I am giving you a different type of statin called rosuvastatin — it works in the same way but is better tolerated by the muscles because it does not penetrate muscle tissue as deeply. Most people who had aching muscles on a previous statin find this one much better tolerated. Take it once daily at any time."
Rosuvastatin: hydrophilic; lower myopathy risk than atorvastatin/simvastatin; preferred in statin-associated muscle symptoms. eGFR <30: max 20mg. Proteinuria: dose-dependent; check urine dipstick at 3 months; do not stop for mild proteinuria. Fewer drug interactions than simvastatin. JUPITER trial: benefit even with normal LDL but elevated CRP. Asian patients: start 10mg (higher plasma levels). Pregnancy: contraindicated.
"This tablet MUST be taken at night — because it is converted to its active form in the liver overnight when cholesterol production is highest. Take it at bedtime every day. And if your doctor adds any new medication, especially for blood pressure or heart rhythm, please tell us you are on simvastatin — because some tablets interact with it and we would need to change the dose or switch tablet."
Simvastatin: must be taken AT NIGHT (prodrug requiring overnight hepatic activation). Multiple CYP3A4 interactions: amlodipine/amiodarone/diltiazem/verapamil max 20mg; ciclosporin contraindicated; gemfibrozil contraindicated. 80mg dose withdrawn — never prescribe. NOT appropriate for David (amlodipine limits simvastatin to 20mg — insufficient). Switch to atorvastatin proactively when new interacting drugs added. All secondary prevention on simvastatin: switch to atorvastatin 80mg.
"This tablet works in a completely different way from the statin — it reduces the amount of cholesterol your gut absorbs from food, rather than lowering the amount your liver makes. Together, they work on both sides of the equation. It is a once-daily tablet that you can take at any time of day. It is generally very well tolerated — some people get some initial stomach upset but this usually settles quickly."
Ezetimibe: add to statin if non-HDL not at target; or monotherapy in statin intolerance. IMPROVE-IT trial: reduces MACE in post-ACS. 15-25% additional LDL reduction. Well tolerated; no significant myopathy risk. Combined product with simvastatin (Inegy): inherits simvastatin drug interactions — check. Pregnancy: contraindicated. Cholestyramine: separate doses by 2-4 hours. First non-statin LDL drug with proven CV event reduction.
"This is an injection you give yourself, usually every 2 weeks, with an auto-injector pen — similar to an insulin pen. Most people find it straightforward. You will keep it in the fridge. The injection goes under the skin of your stomach, thigh, or upper arm — rotate the site each time. It is the most powerful cholesterol-lowering treatment available and reduces your LDL by about half. A nurse will train you before you start."
PCSK9 inhibitors: specialist prescribing only. NICE TA394: secondary prevention with LDL ≥1.8 on max statin + ezetimibe; FH with LDL ≥5.0 on max statin + ezetimibe. 50-60% LDL reduction; fortnightly SC injection. FOURIER trial: 15% MACE reduction on top of statin. Inclisiran (siRNA): similar LDL reduction; twice-yearly injection; NICE approved; preferred for adherence-limited patients. GP role: continue monitoring; annual LDL; injection site review; specialist annual review.
"This is a completely different type of treatment — not a tablet but an injection that you receive twice a year, in the surgery or at the hospital clinic. It works by blocking the gene that produces a protein which reduces your cholesterol-clearing ability. Most people only need two injections per year after the first three months, which makes it much simpler than taking a tablet every day. It reduces LDL cholesterol by about half on top of the statin."
Inclisiran: siRNA; 50% LDL reduction; twice-yearly dosing (Day 1, Day 90, then 6-monthly); NICE TA733. Specialist initiates; GP/primary care can administer ongoing injections. No self-injection required; excellent adherence. NICE criteria: secondary prevention LDL ≥1.8 on max statin ± ezetimibe; FH LDL ≥2.6 on max statin ± ezetimibe. Increasingly preferred over PCSK9 inhibitors (less frequent dosing; no home refrigerator; clinician-administered). Pregnancy: avoid.
Risk as Identity
Being told you have an 18% cardiovascular risk can feel like a new, unwanted identity as someone who is unwell. This can generate either action (motivation to reduce risk) or denial (the risk does not feel real because David feels fine). The GP who explains the risk as a spectrum — not a diagnosis — and frames action as empowering rather than medicating-a-sick-person is more likely to achieve engagement.
"You are not a sick person with a disease. You are a well person with a risk that is worth reducing. The statin is not treatment for an illness — it is insurance against a future event. Most people who have a heart attack felt completely fine the day before."Livelihood and Motivation
David’s HGV licence is his most powerful motivator. The cardiovascular risk is abstract; the HGV licence is concrete. The GP who successfully translates the abstract risk into a concrete occupational risk — "a heart attack at your risk level would take your Group 2 licence for at least 6 weeks" — has made the risk personally relevant. This is a more effective motivational strategy than population statistics alone.
"You have told me your lorry is your livelihood. The thing most likely to threaten that is a heart attack — not the statin. DVLA takes Group 2 licences after heart attacks. The statin reduces the chance of that happening."Shared Decision Making
NICE NG238 explicitly states that statin therapy should be offered through shared decision making — not imposed. David’s autonomy must be respected. If he declines after fully understanding the risk, the GP documents the discussion, ensures a review in 12 months, and continues to address other modifiable factors (smoking, alcohol, diabetes control). The patient who declines once may accept on review when the risk feels more concrete or a family member has a cardiovascular event.
"This is your decision — I am not going to force anything. What I want is for you to make it with the right information. If today you want to try lifestyle changes and come back in 3 months, I can do that. But I would like you to commit to stopping smoking — that is the most powerful thing you can do today."Adherence and Long-Term Treatment
Statin adherence is notoriously poor over time: approximately 50% of patients have stopped their statin within 5 years of starting. The GP who addresses the reasons for potential non-adherence at initiation — side effects (specifically addressed); perceived lack of benefit (explain asymptomatic action); cost (generic atorvastatin is cheap); inconvenience (once daily) — builds the therapeutic relationship that maintains adherence. The patient who understands WHY they are taking a statin and WHAT it is doing is more likely to continue.
"The statin is working even when you feel nothing different. It is reducing the build-up of fatty material in the artery walls silently, every day. You will not feel it. But at your check in 3 months, we will be able to see it in the blood test."Today — Shared Decision Making + Tests + Plan
QRISK3 communicated in plain language (18 in 100). ICE addressed. Myopathy concern addressed specifically. Occupational reframing. Smoking cessation intervention offered (5As; varenicline; NHS Stop Smoking referral). LFTs and TFTs ordered (before statin). eGFR and urine ACR ordered. HbA1c check. BP measured. Discussion: atorvastatin 20mg offered (explain why not simvastatin — amlodipine interaction). SGLT2 inhibitor discussed (empagliflozin/dapagliflozin for T2DM + CVD risk). Alcohol brief intervention. Shared decision: statin to start when results back OR agreement to commit to lifestyle change with statin start at 3-month review.
1-2 Weeks — Blood Test Results
LFTs reviewed: if normal or <3× ULN: start atorvastatin 20mg OD. TFTs: if hypothyroidism found: treat first; reassess lipids when euthyroid. Phone consultation or letter: atorvastatin prescription issued. If results abnormal (>3× ULN transaminase): follow up in person; investigate; defer statin. Smoking cessation follow-up: has he contacted NHS Stop Smoking?
3 Months — Lipid and Treatment Review
Fasting lipid profile: has non-HDL fallen by ≥40% from baseline? (From 4.7 mmol/L: target ≤2.8 mmol/L; ideally <2.5 mmol/L). If not at target: increase atorvastatin to 40mg or add ezetimibe 10mg. Muscle symptoms: any myalgia? If yes: CK check before any dose change. Side effects screen. HbA1c: any change after statin? BP check. Smoking progress: varenicline response. Alcohol: any reduction? SGLT2 inhibitor started?
Annual Review — Comprehensive CVD Risk Reassessment
Repeat QRISK3: has risk reduced with smoking cessation, improved HbA1c, BP control? Annual fasting lipids: is non-HDL at target? If not at target on atorvastatin 40mg + ezetimibe: consider specialist lipid clinic referral. Annual HbA1c, eGFR, urine ACR. BP check. BMI and waist circumference. Smoking status. Alcohol AUDIT. Depression screen (PHQ-9 — CVD and depression comorbidity). Annual diabetic eye and foot screen due? DVLA Group 2 annual medical review (T2DM on oral medication).
Lipid monitoring essentials — NICE NG238
Before starting statin: fasting lipid profile (baseline); LFTs (mandatory); TFTs (screen for hypothyroidism); eGFR; urine ACR. Statin monitoring: fasting lipid profile at 3 months (confirm ≥40% non-HDL reduction); LFTs — only repeat if symptomatic (not routinely); CK — only if muscle symptoms (not routinely). Targets: primary prevention: non-HDL <2.5 mmol/L or LDL-C <1.8 mmol/L; secondary prevention: LDL-C <1.4 mmol/L or non-HDL <2.2 mmol/L. Annual review: lipid profile; HbA1c; BP; weight; smoking; alcohol; eGFR; ACR; DVLA. CK testing: NOT routinely required; ONLY if muscle symptoms develop — a CK level tells the GP whether the symptom represents myopathy (CK >4× ULN) or benign myalgia (normal CK). Routinely measuring CK in asymptomatic statin patients is not recommended and generates false alarms.
⚠ Three safety-net conversations in lipid management
Documentation at every CVD risk consultation
- Prescribing simvastatin instead of atorvastatin — amlodipine limits simvastatin to 20mg (insufficient); atorvastatin is the correct choice
- Starting statin without LFTs — NICE NG238 mandatory before initiation
- Prescribing atorvastatin 80mg for primary prevention — 80mg is secondary prevention dose; primary = 20mg
- Not mentioning smoking cessation as highest-yield intervention
- Dismissing myopathy concern without specific quantified information
- QRISK3 ≥10%: statin offered with shared decision making
- Atorvastatin 20mg correctly selected (not simvastatin — amlodipine interaction; not 80mg — primary prevention)
- LFTs and TFTs ordered before statin
- Myopathy concern addressed with specific numbers (1-3 per 100,000)
- Smoking cessation as highest-yield intervention offered
- SGLT2 inhibitor considered for T2DM + CVD risk
- 3-month lipid target explained (≥40% non-HDL reduction)
- ICE before QRISK3 score delivery
- Myopathy concern validated (friend’s experience real) before corrected
- Occupational reframing (heart attack = licence threat; not statin)
- Risk in concrete terms (18 in 100; not 18%)
- Smoking framed as empowering not punitive
- Shared decision making respected — statin not imposed
Who you are
David Williams, 52, self-employed HGV lorry driver. Long-haul UK routes. Married to Karen. Type 2 diabetes (metformin 1g BD, HbA1c 62). Hypertension (amlodipine 5mg). BMI 32. Smokes 10 cigarettes per day (28 years — 14 pack-years). One previous cessation attempt with patches 4 years ago (lasted 6 weeks). Drinks 3-4 beers most evenings and more at weekends (approximately 16 units per week — doesn’t consider this excessive). Works long hours with limited healthy food options; sedentary at work. Annual diabetic review is up to date. Last eye and foot screen 12 months ago (normal). QRISK3 was calculated by the nurse at 18.3% and he was told he should start a statin at his last appointment — which he declined.
Hidden details — disclose only if asked specifically
Pete’s statin and medications (key unlocking detail): "Pete was on simvastatin — I think 40mg. And yes, now that you mention it, he was also on a tablet for his heart rhythm — amiodarone I think it was called." Only disclose if the GP specifically asks which statin Pete was on AND whether he was on any other heart medication. If the GP identifies this interaction: "So it was the two tablets together that caused it? Not just the statin on its own?" — responds with visible relief and becomes significantly more open to statin discussion.
DVLA concern (disclose if DVLA raised): "I didn’t realise a heart attack would mean I lose my Group 2 licence. How long for exactly?" — this DVLA information is the most powerful motivational shift available; David was not aware of this.
Smoking readiness (disclose if pressed): "Karen keeps asking me to stop. I keep saying I’ll do it when things calm down. But yeah, I know I should." If specifically offered NHS Stop Smoking Service with varenicline: "Does it actually work? What are the chances?" — receptive if given specific success rate information.
Reactions
- On friend’s story explored: if GP asks specifically about Pete’s statin and medications — reveals simvastatin + amiodarone; if GP identifies this as a drug-drug interaction: "Oh — so it was the combination? That makes sense actually. I didn’t know that." Significant shift in attitude to statins.
- On concrete risk framing: "18 out of 100 — so about 1 in 5. That’s more than I thought." Engages concretely with the numbers if framed in population terms rather than as an abstract percentage.
- On DVLA consequences of MI: "I genuinely didn’t know that. Six weeks minimum — that would kill my income. And I might not get the licence back?" — very strong motivational response.
- Challenge line: "What if I’m one of the unlucky ones though? My mate was one of those unlikely cases and it ended his career."
- If simvastatin prescribed: "Oh — but I thought simvastatin was the one that caused Pete’s problems?" — patient catches the prescribing error; serious deduction.
Clinical details
- No chest pain on exertion; no breathlessness; no ankle swelling; no claudication; no TIA symptoms
- No family history of premature CVD (father MI aged 68 — not premature; no tendon xanthomata)
- No symptoms of hypothyroidism; no weight change; no constipation; no cold intolerance
- Peripheral pulses present bilaterally; no arterial bruits; amlodipine 5mg — BP typically around 138/86 on treatment
- Diabetic annual review: last HbA1c 62 mmol/mol; eGFR 74; urine ACR 2.5 (normal); no microalbuminuria; retinal screening normal; no neuropathy symptoms
Resolution: David accepts the consultation as satisfactory and agrees to try the statin if: (1) the friend’s story is engaged specifically and the simvastatin + amiodarone interaction is identified; (2) specific myopathy rates are given (not just "rare"); (3) DVLA Group 2 consequences of MI are explained; (4) risk is framed concretely (18 in 100, not 18%); (5) atorvastatin is prescribed (not simvastatin — if simvastatin is prescribed, David catches the error and the consultation fails); (6) LFTs are ordered before starting; (7) smoking cessation is offered with specific service; (8) the decision is genuinely shared. If these are all met: David says "OK — let’s do the blood tests and start the statin when they come back. And yes — refer me to the smoking service. Karen will be very pleased."
- Prior MI, ACS, stable angina → atorvastatin 80mg (no QRISK3 needed)
- Prior stroke (ischaemic) or TIA → atorvastatin 80mg
- PAD → atorvastatin 80mg + smoking cessation critical
- Target: LDL-C <1.4 mmol/L; add ezetimibe if not at target
- TC >7.5 mmol/L + premature CVD FH → Simon Broome
- Tendon xanthomata → FH regardless of cholesterol
- Start atorvastatin 40-80mg; specialist lipid clinic; cascade screening
- QRISK3 ≥10%: offer atorvastatin 20mg; shared decision
- QRISK3 <10%: lifestyle; repeat QRISK3 in 5 years
- LFTs + TFTs before starting; 3-month check (≥40% non-HDL reduction)